News Story: Full Text
Sponsored By
AbbVie
Please Click On The Above Banner For More Details
Braintumor Website

 

Clinical Trial Announcement Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Glioblastoma at First Recurrence or Progression

Al's Comment:

 Disclosure: the company that makes this is a sponsor of the Musella Foundation

This is an exciting trial.  It is similar (although it uses a different target) to a trial done a long time ago that failed because the state of the art in convection enhanced delivery at that time did not allow the drug to get to the entire tumor.  Now the technology has improved to the point where it can deliver the drug to just about anywhere we want it to go!  A major advantage of this type of treatment over other immunotherapies is that it does not rely on your immune system to help it. The fusion protein binds to the IL-4 receptor (which about 80% of glioblastomas over-express, and normal cells do not express), and carried the toxin to those cells - which makes this a smart bomb type of approach - it should theoretically kill tumor cells and not normal cells.


Posted on: 03/10/2017

Clinical Trial Announcement
Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Glioblastoma at First Recurrence or Progression
 
 
Official Title: An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Glioblastoma at First Recurrence or Progression
 
This is a single-arm, open-label, multicenter study in approximately 43 adults with primary (de novo) Glioblastoma that has recurred or progressed after failure of first -line therapy [according to Response Assessment in Neuro-Oncology (RANO) criteria]. Eligible subjects will receive intratumoral infusion of MDNA55 administered via convection-enhanced delivery (CED).
 
MDNA55, is a fusion protein comprising a genetically engineered Interleukin-4 (IL-4) linked to a modified version of the Pseudomonas aeruginosa exotoxin A (PE).
 
Participating Hospitals: 
University of California San Francisco (San Francisco, CA)
Duke University Medical Center (Durham, NC)
Cleveland Clinic (Cleveland, OH)
University of Texas Southwestern Medical Center (Dallas, TX)
University of Texas Health Science Center -  San Antonio  (San Antonio, TX)
Ohio State University (Columbus, OH)
John Wayne Cancer Institute at Providence Saint John’s Health Center (Santa Monica, CA)
Weill Cornell – New York Presbyterian Hospital (New York, NY)
Marcus Neuroscience Institute   (Boca Raton, FL) / South Florida)
 
For more information on study details and contact details for participating hospitals please visit:
 
ClinicalTrials.Gov
https://clinicaltrials.gov/ct2/show/NCT02858895 
 
Medicenna Website:
http://www.medicenna.com
 http://www.medicenna.com/Our-Lead-Program/Clinical-Trials/default.aspx  
 
Medicenna Contact::
Melissa Coella, Director of Clinical Operations, Phone: 267-476-2313
 

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740